Japan — Pharmaceuticals and Medical Devices Agency
Tracked across 7 events · 48 articles · First seen May 12, 2026 · Last active Sep 22, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: The PMDA is the regulatory authority reviewing Natera's application. Its decision will determine market access for Signatera in MIBC in Japan.
Aug 05, 2026 · 7 articles
Regulatory
Impact: PMDA conducted a Pre-Approval Inspection, enabling Cambrex's High Point facility to manufacture APIs for the Japanese market.
Jul 20, 2026 · 8 articles
Regulatory
Natera announced that its Signatera test received regulatory approval from Japan's Japan — Pharmaceuticals and Medical Devices Agency as a companion diagnostic in muscle-invasive bladder cancer. The approval supports the use of Signatera to guide…
Impact: Japan's regulator granted the companion diagnostic approval for Signatera in muscle-invasive bladder cancer, enabling Natera's planned Japanese launch.
Sep 22, 2026 · 6 articles
Tech
Impact: The BD BACTEC FXI Culture System was licensed by the Japan — Pharmaceuticals and Medical Devices Agency for availability in Japan.
Jun 03, 2026 · 8 articles
Business
Impact: One of the acquired facilities underwent a Japan — Pharmaceuticals and Medical Devices Agency review in 2025 with clean results, demonstrating international regulatory compliance.
Jul 02, 2026 · 7 articles
Business
Impact: Japan's regulatory agency stated most new drugs require Japanese patient data, not solely Chinese studies.
Jul 15, 2026 · 6 articles
95
Japan — Pharmaceuticals and Medical Devices Agency approved Signatera companion diagnostic NateraNatera Signatera PMDA...
ERGEN INTELLIGENCE
Track Japan — Pharmaceuticals and Medical Devices Agency live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard